Efstathios Kastritis, MD, on Implications of Positive Results From the Phase 3 ANDROMEDA Study

At the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Efstathios Kastritis, MD, professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, to discuss the phase 3 ANDROMEDA trial (NCT03201965). The expert detailed what these results mean for the treatment of patients with newly diagnosed light chain (AL) amyloidosis with subcutaneous daratumumab (DARA; Darzalex) plus bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCd) moving forward.

Transcription:

Based on the results of the ANDROMEDA study, the combination of daratumumab with VCd has become the first official approved therapy for AL amyloidosis. So first of all, our patients will finally have a very effective therapy that is also quite safe since we didn’t see any additional safety signals with the combinations with the addition of daratumumab to VCd.

The improvement in the complete hematologic response rates is very important because we know that this is the most important factor associated with the improvement in overall survival and also with improvement in organ function. Actually, this is where we see a doubling of organ response rates, which probably will further improve in the future.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol. 2021;39(suppl 15):8003. doi:10.1200/JCO.2021.39.15_suppl.8003